Skip to Main Content


Aducanumab, a monoclonal antibody that targets amyloid-beta protein and promotes its clearance from the brain, became the first new drug approved by the FDA for the treatment of Alzheimer disease since 2003.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.